Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 284

1.

Tumour Treating Fields (TTFields) in combination with lomustine and temozolomide in patients with newly diagnosed glioblastoma.

Lazaridis L, Schäfer N, Teuber-Hanselmann S, Blau T, Schmidt T, Oster C, Weller J, Tzaridis T, Pierscianek D, Keyvani K, Kleinschnitz C, Stuschke M, Scheffler B, Deuschl C, Sure U, Herrlinger U, Kebir S, Glas M.

J Cancer Res Clin Oncol. 2019 Dec 11. doi: 10.1007/s00432-019-03106-8. [Epub ahead of print]

PMID:
31828428
2.

Clinical Implication of Dosimetry of Computed Tomography- and Fluoroscopy-Guided Intrathecal Therapy With Nusinersen in Adult Patients With Spinal Muscular Atrophy.

Kizina K, Stolte B, Totzeck A, Bolz S, Fleischer M, Mönninghoff C, Guberina N, Oldenburg D, Forsting M, Kleinschnitz C, Hagenacker T.

Front Neurol. 2019 Nov 5;10:1166. doi: 10.3389/fneur.2019.01166. eCollection 2019.

3.

Should IV Thrombolysis be given in Patients with Suspected Ischemic Stroke but Unknown Symptom Onset and Without Diffusion-Weighted Imaging Lesion? - Results of a Case-Control Study.

Seyhan M, Mackenrodt D, Gunreben I, Müllges W, Häusler KG, Pham M, Kleinschnitz C, Kraft P.

J Stroke Cerebrovasc Dis. 2019 Nov 27:104515. doi: 10.1016/j.jstrokecerebrovasdis.2019.104515. [Epub ahead of print]

PMID:
31786042
4.

Neurofilament Heavy Chain and Tau Protein Are Not Elevated in Cerebrospinal Fluid of Adult Patients with Spinal Muscular Atrophy during Loading with Nusinersen.

Totzeck A, Stolte B, Kizina K, Bolz S, Schlag M, Thimm A, Kleinschnitz C, Hagenacker T.

Int J Mol Sci. 2019 Oct 30;20(21). pii: E5397. doi: 10.3390/ijms20215397.

5.

Simultaneous primary cancer occurrence of melanoma and pulmonary adenocarcinoma in leptomeningeal metastases: a case report.

Stoppek AK, Kebir S, Junker A, Keyvani K, Zülow S, Lazaridis L, Schmidt T, Pierscianek D, Stuschke M, Sure U, Kleinschnitz C, Scheffler B, Zimmer L, Glas M.

BMC Cancer. 2019 Oct 23;19(1):995. doi: 10.1186/s12885-019-6183-2.

6.

Deactivation of ATP-Binding Cassette Transporters ABCB1 and ABCC1 Does Not Influence Post-ischemic Neurological Deficits, Secondary Neurodegeneration and Neurogenesis, but Induces Subtle Microglial Morphological Changes.

Manrique-Castano D, Sardari M, Silva de Carvalho T, Doeppner TR, Popa-Wagner A, Kleinschnitz C, Chan A, Hermann DM.

Front Cell Neurosci. 2019 Sep 12;13:412. doi: 10.3389/fncel.2019.00412. eCollection 2019.

7.

[Update on antithrombotic secondary prevention of ischemic stroke].

Köhrmann M, Kleinschnitz C.

Nervenarzt. 2019 Oct;90(10):995-1004. doi: 10.1007/s00115-019-00788-w. Review. German.

PMID:
31560112
8.

Loss of Orai2-Mediated Capacitative Ca2+ Entry Is Neuroprotective in Acute Ischemic Stroke.

Stegner D, Hofmann S, Schuhmann MK, Kraft P, Herrmann AM, Popp S, Höhn M, Popp M, Klaus V, Post A, Kleinschnitz C, Braun A, Meuth SG, Lesch KP, Stoll G, Kraft R, Nieswandt B.

Stroke. 2019 Nov;50(11):3238-3245. doi: 10.1161/STROKEAHA.119.025357. Epub 2019 Sep 25.

PMID:
31551038
9.

Health outcome of older hospitalized patients in internal medicine environments evaluated by Identification of Seniors at Risk (ISAR) screening and geriatric assessment.

Scharf AC, Gronewold J, Dahlmann C, Schlitzer J, Kribben A, Gerken G, Rassaf T, Kleinschnitz C, Dodel R, Frohnhofen H, Hermann DM.

BMC Geriatr. 2019 Aug 14;19(1):221. doi: 10.1186/s12877-019-1239-3.

10.

Validity and Reliability of Neurological Scores in Mice Exposed to Middle Cerebral Artery Occlusion.

Bieber M, Gronewold J, Scharf AC, Schuhmann MK, Langhauser F, Hopp S, Mencl S, Geuss E, Leinweber J, Guthmann J, Doeppner TR, Kleinschnitz C, Stoll G, Kraft P, Hermann DM.

Stroke. 2019 Oct;50(10):2875-2882. doi: 10.1161/STROKEAHA.119.026652. Epub 2019 Aug 15.

PMID:
31412755
11.

Glyphosate-based herbicide: a risk factor for demyelinating conditions of the peripheral nervous system?

Szepanowski F, Kleinschnitz C, Stettner M.

Neural Regen Res. 2019 Dec;14(12):2079-2080. doi: 10.4103/1673-5374.262579. No abstract available.

12.

Pretreatment anti-thyroid autoantibodies indicate increased risk for thyroid autoimmunity secondary to alemtuzumab: A prospective cohort study.

Ruck T, Schulte-Mecklenbeck A, Pfeuffer S, Heming M, Klotz L, Windhagen S, Kleinschnitz C, Gross CC, Wiendl H, Meuth SG.

EBioMedicine. 2019 Aug;46:381-386. doi: 10.1016/j.ebiom.2019.07.062. Epub 2019 Jul 29.

13.

Moderate Protein Restriction Protects Against Focal Cerebral Ischemia in Mice by Mechanisms Involving Anti-inflammatory and Anti-oxidant Responses.

de Carvalho TS, Sanchez-Mendoza EH, Nascentes LM, Schultz Moreira AR, Sardari M, Dzyubenko E, Kleinschnitz C, Hermann DM.

Mol Neurobiol. 2019 Dec;56(12):8477-8488. doi: 10.1007/s12035-019-01679-6. Epub 2019 Jul 1.

14.

Computer aided diagnosis for ASPECT rating: initial experiences with the Frontier ASPECT Score software.

Goebel J, Stenzel E, Zuelow S, Kleinschnitz C, Forsting M, Moenninghoff C, Radbruch A.

Acta Radiol. 2019 Dec;60(12):1673-1679. doi: 10.1177/0284185119842465. Epub 2019 Apr 24. No abstract available.

PMID:
31018652
15.

Comparison of L-Methyl-11C-Methionine PET With Magnetic Resonance Spectroscopy in Detecting Newly Diagnosed Glioma.

Kebir S, Lazaridis L, Weber M, Deuschl C, Stoppek AK, Schmidt T, Mönninghoff C, Blau T, Keyvani K, Umutlu L, Pierscianek D, Forsting M, Stuschke M, Antoch G, Sure U, Kleinschnitz C, Scheffler B, Colletti PM, Rubello D, Herrmann K, Glas M.

Clin Nucl Med. 2019 Jun;44(6):e375-e381. doi: 10.1097/RLU.0000000000002577.

PMID:
30985412
16.

Modeling Vascular Risk Factors for the Development of Ischemic Stroke Therapies.

Hermann DM, Kleinschnitz C.

Stroke. 2019 May;50(5):1310-1317. doi: 10.1161/STROKEAHA.118.024673. No abstract available.

PMID:
30896361
17.

Longitudinal heterogeneity in glioblastoma: moving targets in recurrent versus primary tumors.

Schäfer N, Gielen GH, Rauschenbach L, Kebir S, Till A, Reinartz R, Simon M, Niehusmann P, Kleinschnitz C, Herrlinger U, Pietsch T, Scheffler B, Glas M.

J Transl Med. 2019 Mar 20;17(1):96. doi: 10.1186/s12967-019-1846-y.

18.

Neuroprotection Induced by Energy and Protein-Energy Undernutrition Is Phase-Dependent After Focal Cerebral Ischemia in Mice.

de Carvalho TS, Sanchez-Mendoza EH, Nascentes Melo LM, Schultz Moreira AR, Sardari M, Dzyubenko E, Kleinschnitz C, Hermann DM.

Transl Stroke Res. 2019 Mar 18. doi: 10.1007/s12975-019-00700-3. [Epub ahead of print]

PMID:
30887279
19.

Relative health-related quality of life after treatment of unruptured intracranial aneurysms: long-term outcomes and influencing factors.

Dammann P, Wittek P, Darkwah Oppong M, Hütter BO, Jabbarli R, Wrede K, Wanke I, Mönninghoff C, Kaier K, Frank B, Müller O, Kleinschnitz C, Forsting M, Sure U.

Ther Adv Neurol Disord. 2019 Mar 8;12:1756286419833492. doi: 10.1177/1756286419833492. eCollection 2019.

20.

Calcium-dependent blood-brain barrier breakdown by NOX5 limits postreperfusion benefit in stroke.

Casas AI, Kleikers PW, Geuss E, Langhauser F, Adler T, Busch DH, Gailus-Durner V, de Angelis MH, Egea J, Lopez MG, Kleinschnitz C, Schmidt HH.

J Clin Invest. 2019 Mar 18;130:1772-1778. doi: 10.1172/JCI124283. eCollection 2019 Mar 18.

21.

Radiation exposure of image-guided intrathecal administration of nusinersen to adult patients with spinal muscular atrophy.

Oldenburg D, Guberina N, Stolte B, Kizina K, Stenzel E, Radbruch A, Kleinschnitz C, Hagenacker T, Forsting M, Mönninghoff C.

Neuroradiology. 2019 May;61(5):565-574. doi: 10.1007/s00234-019-02189-x. Epub 2019 Mar 14.

PMID:
30868184
22.

Sleep-Disordered Breathing in Hospitalized Geriatric Patients with Mild Dementia and Its Association with Cognition, Emotion and Mobility.

Gronewold J, Haensel R, Kleinschnitz C, Frohnhofen H, Hermann DM.

Int J Environ Res Public Health. 2019 Mar 9;16(5). pii: E863. doi: 10.3390/ijerph16050863.

23.

Immunology of stroke: from animal models to clinical trials.

Schmidt-Pogoda A, Minnerup J, Kleinschnitz C.

Ther Adv Neurol Disord. 2019 Feb 21;12:1756286419830862. doi: 10.1177/1756286419830862. eCollection 2019. No abstract available.

24.

Regorafenib in patients with recurrent high-grade astrocytoma.

Kebir S, Rauschenbach L, Radbruch A, Lazaridis L, Schmidt T, Stoppek AK, Pierscianek D, Stuschke M, Forsting M, Sure U, Keyvani K, Kleinschnitz C, Scheffler B, Glas M.

J Cancer Res Clin Oncol. 2019 Apr;145(4):1037-1042. doi: 10.1007/s00432-019-02868-5. Epub 2019 Feb 28.

PMID:
30820715
25.

A fatal case of daclizumab-induced liver failure in a patient with MS.

Stettner M, Gross CC, Mausberg AK, Pul R, Junker A, Baba HA, Schulte-Mecklenbeck A, Wiendl H, Kleinschnitz C, Meuth SG.

Neurol Neuroimmunol Neuroinflamm. 2019 Jan 21;6(2):e539. doi: 10.1212/NXI.0000000000000539. eCollection 2019 Mar. No abstract available.

26.

Overcoming trivialization: The neuroimmune response after acute central nervous system injury.

Schwab JM, Kleinschnitz C.

J Neuroimmunol. 2019 May 15;330:28-30. doi: 10.1016/j.jneuroim.2019.01.018. Epub 2019 Jan 31. No abstract available.

PMID:
30772755
27.

Animal models of ischemic stroke and their impact on drug discovery.

Hermann DM, Popa-Wagner A, Kleinschnitz C, Doeppner TR.

Expert Opin Drug Discov. 2019 Mar;14(3):315-326. doi: 10.1080/17460441.2019.1573984. Epub 2019 Feb 4.

PMID:
30714423
28.

Intracranial Aneurysms in Sickle Cell Disease.

Jabbarli R, Dinger TF, Pierscianek D, Oppong MD, Chen B, Dammann P, Wrede KH, Kaier K, Köhrmann M, Forsting M, Kleinschnitz C, Sure U.

Curr Neurovasc Res. 2019;16(1):63-76. doi: 10.2174/1567202616666190131160847.

PMID:
30706782
29.

Feasibility of intra-arterial chemotherapy for retinoblastoma: experiences in a large single center cohort study.

Stenzel E, Göricke S, Temming P, Biewald E, Zülow S, Göbel J, Wanke I, Umutlu L, Kleinschnitz C, Bornfeld N, Forsting M, Radbruch A, Mönninghoff C.

Neuroradiology. 2019 Mar;61(3):351-357. doi: 10.1007/s00234-019-02153-9. Epub 2019 Jan 14.

PMID:
30643921
30.

Role of immune responses for extracellular matrix remodeling in the ischemic brain.

Dzyubenko E, Manrique-Castano D, Kleinschnitz C, Faissner A, Hermann DM.

Ther Adv Neurol Disord. 2018 Dec 17;11:1756286418818092. doi: 10.1177/1756286418818092. eCollection 2018. Review.

31.

[Treatment evaluation in patients with 5q-associated spinal muscular atrophy : Real-world experience].

Walter MC, Dräger B, Günther R, Hermann A, Hagenacker T, Kleinschnitz C, Löscher W, Meyer T, Schrank B, Schwersenz I, Wurster CD, Ludolph AC, Kirschner J.

Nervenarzt. 2019 Apr;90(4):343-351. doi: 10.1007/s00115-018-0653-7. Review. German.

PMID:
30617569
32.

Effectiveness of Endovascular Recanalization Treatment for M2 Segment Occlusion: Comparison Between Intracranial ICA, M1, and M2 Segment Thrombectomy.

Goebel J, Stenzel E, Wanke I, Paech D, Koehrmann M, Kleinschnitz C, Forsting M, Radbruch A, Moenninghoff C.

Acad Radiol. 2019 Oct;26(10):e298-e304. doi: 10.1016/j.acra.2018.11.019. Epub 2018 Dec 24.

PMID:
30587388
33.

Description of a Novel Phosphodiesterase (PDE)-3 Inhibitor Protecting Mice From Ischemic Stroke Independent From Platelet Function.

Bieber M, Schuhmann MK, Volz J, Kumar GJ, Vaidya JR, Nieswandt B, Pham M, Stoll G, Kleinschnitz C, Kraft P.

Stroke. 2019 Feb;50(2):478-486. doi: 10.1161/STROKEAHA.118.023664.

34.

Plasma kallikrein modulates immune cell trafficking during neuroinflammation via PAR2 and bradykinin release.

Göbel K, Asaridou CM, Merker M, Eichler S, Herrmann AM, Geuß E, Ruck T, Schüngel L, Groeneweg L, Narayanan V, Schneider-Hohendorf T, Gross CC, Wiendl H, Kehrel BE, Kleinschnitz C, Meuth SG.

Proc Natl Acad Sci U S A. 2019 Jan 2;116(1):271-276. doi: 10.1073/pnas.1810020116. Epub 2018 Dec 17.

35.

Post-treatment Antiplatelet Therapy Reduces Risk for Delayed Cerebral Ischemia due to Aneurysmal Subarachnoid Hemorrhage.

Darkwah Oppong M, Gembruch O, Pierscianek D, Köhrmann M, Kleinschnitz C, Deuschl C, Mönninghoff C, Kaier K, Forsting M, Sure U, Jabbarli R.

Neurosurgery. 2019 Dec 1;85(6):827-833. doi: 10.1093/neuros/nyy550.

PMID:
30544176
36.

Hybrid 11C-MET PET/MRI Combined With "Machine Learning" in Glioma Diagnosis According to the Revised Glioma WHO Classification 2016.

Kebir S, Weber M, Lazaridis L, Deuschl C, Schmidt T, Mönninghoff C, Keyvani K, Umutlu L, Pierscianek D, Forsting M, Sure U, Stuschke M, Kleinschnitz C, Scheffler B, Colletti PM, Rubello D, Rischpler C, Glas M.

Clin Nucl Med. 2019 Mar;44(3):214-220. doi: 10.1097/RLU.0000000000002398.

PMID:
30516675
37.

Efficacy and safety of alemtuzumab versus fingolimod in RRMS after natalizumab cessation.

Pfeuffer S, Schmidt R, Straeten FA, Pul R, Kleinschnitz C, Wieshuber M, Lee DH, Linker RA, Doerck S, Straeten V, Windhagen S, Pawlitzki M, Aufenberg C, Lang M, Eienbroeker C, Tackenberg B, Limmroth V, Wildemann B, Haas J, Klotz L, Wiendl H, Ruck T, Meuth SG.

J Neurol. 2019 Jan;266(1):165-173. doi: 10.1007/s00415-018-9117-z. Epub 2018 Nov 16.

PMID:
30446966
38.

Differential impact of pure glyphosate and glyphosate-based herbicide in a model of peripheral nervous system myelination.

Szepanowski F, Szepanowski LP, Mausberg AK, Albrecht P, Kleinschnitz C, Kieseier BC, Stettner M.

Acta Neuropathol. 2018 Dec;136(6):979-982. doi: 10.1007/s00401-018-1938-4. Epub 2018 Nov 16. No abstract available.

PMID:
30446820
39.

How is the formation of microthrombi after traumatic brain injury linked to inflammation?

Albert-Weissenberger C, Hopp S, Nieswandt B, Sirén AL, Kleinschnitz C, Stetter C.

J Neuroimmunol. 2019 Jan 15;326:9-13. doi: 10.1016/j.jneuroim.2018.10.011. Epub 2018 Oct 31. Review.

PMID:
30445364
40.

Absence of Regulatory T Cells Causes Phenotypic and Functional Switch in Murine Peritoneal Macrophages.

Skuljec J, Jirmo AC, Habener A, Talbot SR, Pul R, Grychtol R, Aydin M, Kleinschnitz C, Happle C, Hansen G.

Front Immunol. 2018 Oct 31;9:2458. doi: 10.3389/fimmu.2018.02458. eCollection 2018.

41.

Vitiligo after alemtuzumab treatment: Secondary autoimmunity is not all about B cells.

Ruck T, Pfeuffer S, Schulte-Mecklenbeck A, Gross CC, Lindner M, Metze D, Ehrchen J, Sondermann W, Pul R, Kleinschnitz C, Wiendl H, Meuth SG, Klotz L.

Neurology. 2018 Dec 11;91(24):e2233-e2237. doi: 10.1212/WNL.0000000000006648. Epub 2018 Nov 7.

42.

Polarity-specific modulation of pain processing by transcranial direct current stimulation - a blinded longitudinal fMRI study.

Naegel S, Biermann J, Theysohn N, Kleinschnitz C, Diener HC, Katsarava Z, Obermann M, Holle D.

J Headache Pain. 2018 Oct 24;19(1):99. doi: 10.1186/s10194-018-0924-5.

43.

Postacute Delivery of GABAA α5 Antagonist Promotes Postischemic Neurological Recovery and Peri-infarct Brain Remodeling.

Wang YC, Dzyubenko E, Sanchez-Mendoza EH, Sardari M, Silva de Carvalho T, Doeppner TR, Kaltwasser B, Machado P, Kleinschnitz C, Bassetti CL, Hermann DM.

Stroke. 2018 Oct;49(10):2495-2503. doi: 10.1161/STROKEAHA.118.021378.

44.

Gute Ernährung reduziert MS-Symptome.

Pul R, Kleinschnitz C.

MMW Fortschr Med. 2018 Oct;160(18):42. doi: 10.1007/s15006-018-1026-7. Review. German. No abstract available.

PMID:
30350066
45.

Apheresis therapies for NMOSD attacks: A retrospective study of 207 therapeutic interventions.

Kleiter I, Gahlen A, Borisow N, Fischer K, Wernecke KD, Hellwig K, Pache F, Ruprecht K, Havla J, Kümpfel T, Aktas O, Hartung HP, Ringelstein M, Geis C, Kleinschnitz C, Berthele A, Hemmer B, Angstwurm K, Stellmann JP, Schuster S, Stangel M, Lauda F, Tumani H, Mayer C, Krumbholz M, Zeltner L, Ziemann U, Linker R, Schwab M, Marziniak M, Then Bergh F, Hofstadt-van Oy U, Neuhaus O, Zettl UK, Faiss J, Wildemann B, Paul F, Jarius S, Trebst C; NEMOS (Neuromyelitis Optica Study Group).

Neurol Neuroimmunol Neuroinflamm. 2018 Sep 26;5(6):e504. doi: 10.1212/NXI.0000000000000504. eCollection 2018 Nov.

46.

Laboratory biomarkers of delayed cerebral ischemia after subarachnoid hemorrhage: a systematic review.

Jabbarli R, Pierscianek D, Darkwah Oppong M, Sato T, Dammann P, Wrede KH, Kaier K, Köhrmann M, Forsting M, Kleinschnitz C, Roos A, Sure U.

Neurosurg Rev. 2018 Oct 10. doi: 10.1007/s10143-018-1037-y. [Epub ahead of print] Review.

PMID:
30306357
47.

Feasibility and safety of intrathecal treatment with nusinersen in adult patients with spinal muscular atrophy.

Stolte B, Totzeck A, Kizina K, Bolz S, Pietruck L, Mönninghoff C, Guberina N, Oldenburg D, Forsting M, Kleinschnitz C, Hagenacker T.

Ther Adv Neurol Disord. 2018 Oct 5;11:1756286418803246. doi: 10.1177/1756286418803246. eCollection 2018.

48.

Role of polymorphonuclear neutrophils in the reperfused ischemic brain: insights from cell-type-specific immunodepletion and fluorescence microscopy studies.

Hermann DM, Kleinschnitz C, Gunzer M.

Ther Adv Neurol Disord. 2018 Sep 14;11:1756286418798607. doi: 10.1177/1756286418798607. eCollection 2018. Review.

49.

Symptomatology and symptomatic treatment in multiple sclerosis: Results from a nationwide MS registry.

Rommer PS, Eichstädt K, Ellenberger D, Flachenecker P, Friede T, Haas J, Kleinschnitz C, Pöhlau D, Rienhoff O, Stahmann A, Zettl UK.

Mult Scler. 2019 Oct;25(12):1641-1652. doi: 10.1177/1352458518799580. Epub 2018 Sep 19.

PMID:
30230952
50.

Automated ASPECT rating: comparison between the Frontier ASPECT Score software and the Brainomix software.

Goebel J, Stenzel E, Guberina N, Wanke I, Koehrmann M, Kleinschnitz C, Umutlu L, Forsting M, Moenninghoff C, Radbruch A.

Neuroradiology. 2018 Dec;60(12):1267-1272. doi: 10.1007/s00234-018-2098-x. Epub 2018 Sep 15.

PMID:
30219935

Supplemental Content

Loading ...
Support Center